135 related articles for article (PubMed ID: 36937463)
1. Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample.
Hussein ZR; Omar SK; Alkazraji RAM; Alsamarrai AN; Alrubaye HS; Al-Hussaniy HA
J Med Life; 2023 Feb; 16(2):235-243. PubMed ID: 36937463
[TBL] [Abstract][Full Text] [Related]
2. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
3. [Three-year follow-up study of clinical effectiveness of antiangiogenic therapy for neovascular age-related macular degeneration].
Fursova AZ; Nikulich IF; Dmitrieva EI; Gusarevich OG; Derbeneva AS; Vasilyeva MA; Kozhevnikova OS; Kolosova NG
Vestn Oftalmol; 2023; 139(5):45-52. PubMed ID: 37942596
[TBL] [Abstract][Full Text] [Related]
4. Correlations between subfoveal choroidal thickness, macular thickness, and visual outcome in neovascular age-related macular degeneration using swept source OCT: insights from intravitreal aflibercept treatment.
Beraldo DP; Rezende MP; Alexander JG; Polido J; Belfort R; Cabral T
Int J Retina Vitreous; 2023 Nov; 9(1):70. PubMed ID: 37968771
[TBL] [Abstract][Full Text] [Related]
5. Choroidal remodeling following different anti-VEGF therapies in neovascular AMD.
Boscia G; Pozharitskiy N; Grassi MO; Borrelli E; D'Addario M; Alessio G; Boscia F; Viggiano P
Sci Rep; 2024 Jan; 14(1):1941. PubMed ID: 38253789
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration.
Balaratnasingam C; Dhrami-Gavazi E; McCann JT; Ghadiali Q; Freund KB
Clin Ophthalmol; 2015; 9():2355-71. PubMed ID: 26719668
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD.
Viggiano P; Miere A; Borrelli E; Boscia G; Grassi MO; Souied EH; Alessio G; Boscia F
Invest Ophthalmol Vis Sci; 2023 Nov; 64(14):32. PubMed ID: 37988106
[TBL] [Abstract][Full Text] [Related]
8. Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis.
Victor AA; Putri YM
Int J Retina Vitreous; 2022 Sep; 8(1):67. PubMed ID: 36138445
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases.
HodjatJalali K; Mehravaran S; Faghihi H; Hashemi H; Kazemi P; Rastad H
J Curr Ophthalmol; 2017 Sep; 29(3):228-231. PubMed ID: 28913517
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic Association between Allelic Variants of the Autophagy-Related Genes and Anti-Vascular Endothelial Growth Factor Treatment Response in Neovascular Age-Related Macular Degeneration.
Kozhevnikova OS; Fursova AZ; Derbeneva AS; Nikulich IF; Devyatkin VA; Kolosova NG
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002079
[TBL] [Abstract][Full Text] [Related]
11. Vision protection therapy for prevention of neovascular age-related macular degeneration.
Luttrull JK; Gray G; Bhavan SV
Sci Rep; 2023 Oct; 13(1):16710. PubMed ID: 37794027
[TBL] [Abstract][Full Text] [Related]
12. Long term follow up of patients with MNV3 treated with intra-vitreal Aflibercept.
Browning AC; Grinton ME; Quinn S; Jain T; Manikavasagar V; Aftab AM
Eur J Ophthalmol; 2024 Feb; ():11206721241229912. PubMed ID: 38304945
[TBL] [Abstract][Full Text] [Related]
13. Psychophysical, electrofunctional, and morphological evaluation in naïve neovascular AMD patients treated with intravitreal anti-VEGF.
Nebbioso M; Franzone F; Milanese A; Artico M; Taurone S; La Cava M; Livani ML; Bonfiglio V; Vestri A
Aging Med (Milton); 2024 Apr; 7(2):189-201. PubMed ID: 38725692
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Bek T; Sørensen TL
Ugeskr Laeger; 2023 Nov; 185(48):. PubMed ID: 38018728
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration.
Hara C; Suzue M; Fujimoto S; Fukushima Y; Sayanagi K; Nishida K; Maruyama K; Sato S; Nishida K
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256517
[TBL] [Abstract][Full Text] [Related]
16. Injection burden and treatment intervals of aflibercept in observe-and-plan regimen for neovascular age-related macular degeneration.
Subhi Y; Schneider M; Hajari JN; la Cour M
Acta Ophthalmol; 2024 May; ():. PubMed ID: 38733136
[TBL] [Abstract][Full Text] [Related]
17. Association between non-steroidal anti-inflammatory drug use and development of age-related macular degeneration-A 10-year retrospective cohort study.
Yang TM; Huang WL; Yang CH; Yang CM; Ho TC; Chen TC; Lai TT; Hsieh YT
J Formos Med Assoc; 2024 Apr; 123(4):467-477. PubMed ID: 37858375
[TBL] [Abstract][Full Text] [Related]
18. [Topical treatment for age-related macular degeneration: Where are we now?].
Pierre M; Lamaa D; Fabre M; Ronco C; Benhida R; Demange L; Charrueau C
Med Sci (Paris); 2023 Dec; 39(12):958-966. PubMed ID: 38108727
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
